With STI rates on the rise, cobas® CT/NG provides a solution to meet the growing demand for CT/NG Testing, delivering exceptional assay performance, providing broader information for improved patient care decisions, and enabling simplicity and flexibility to support varying throughput and workflow requirements.
The cobas® CT/NG for use on the cobas® 5800/6800/8800 Systems is an automated, qualitative in vitro nucleic diagnostic test, that utilises real-time polymerase chain reaction (PCR), for the direct detection of Chlamydia trachomatis (CT) and/or Neisseria gonorrhoeae (NG) DNA in male and female urine, clinician-instructed self-collected vaginal swab specimens, clinician-collected vaginal swab specimens, endocervical swab specimens, oropharyngeal (throat) and anorectal swab specimens, all collected in cobas® PCR Media (Roche Molecular Systems, Inc.), and cervical specimens collected in PreservCyt® Solution. This test is intended as an aid in the diagnosis of chlamydial and gonococcal disease in both symptomatic and asymptomatic individuals.
CE-IVD
Access package inserts through Roche DiaLog.